By Stu Hutson In the US, the query of whether pharmaceutical companies will be able to pay off competitors challenging their patent exclusivity might now be left to Congress.8M NIH grant supports multi-center, multidisciplinary study in deadly bleeding syndrome A fresh five-year, $23.8 million National Institutes of Health grant will support a multi-center, multidisciplinary study on a deadly bleeding syndrome – called coagulopathy – occurring without warning in some trauma individuals. Led by University of Vermont Professor Emeritus of Biochemistry Kenneth Mann, Ph.D., the TACTIC study is a cooperative work funded by the National Center, Bloodstream and Lung Institute that establishes a unique collaboration between your NIH and the Department of Defense.The usage of mepolizumab resulted in a relative reduction in the rate of exacerbations needing hospitalization or a crisis department visit of 32 percent in the intravenous-mepolizumab group and 61 percent in the subcutaneous-mepolizumab group . Identical reductions were observed in mepolizumab-treated groups regarding exacerbations leading to hospitalization . The cumulative number of exacerbations as time passes is shown in Shape 2AFigure 2Asthma Exacerbations and FEV1 at 32 Weeks. Data regarding the time to the 1st exacerbation and the indicate duration of exposure to systemic glucocorticoids are given in Fig.